摘要
抗体偶联药物(ADC)是通过单克隆抗体与小分子抗肿瘤药物以特定连接方式组成的靶向生物药物,以单克隆抗体为载体将高度杀伤作用的小分子肿瘤药物定向递送至肿瘤细胞处,起到杀灭肿瘤细胞的作用。ADC以其精准的药物递送靶向性能,减少化疗药物的毒性反应,提高治疗效果,为传统化疗治疗效果较差及无法耐受患者提供新的选择方案。随着研究的不断深入,ADC在多种实体瘤临床应用中取得良好应用效果,并且为常规化疗治疗无效的胃癌患者的治疗提供新的方案。因此,深入探析ADC分子结构、作用机制、临床应用中适应症、用药方案选择及安全性管理,对于此类药物的临床合理应用有重要意义。为此,本文通过对ADC分子结构、作用机制、新型ADC研究进展、ADC在胃癌患者中应用的研究进展进行综述,以期为ADC类药物的临床合理应用提供参考依据。
Antibody-drug conjugates(ADCs) are targeted biological drugs composed of monoclonal antibodies and small molecule anti-tumor drugs in a characteristic connection manner.Using monoclonal antibodies as carriers,highly lethal small molecule tumor drugs are delivered to tumor cells in a targeted manner,playing a role in killing tumor cells.ADC,with its precise drug delivery targeting performance,reduces the toxic reactions of chemotherapy drugs,improves treatment efficacy,and provides a new option for patients with poor efficacy and intolerance to traditional chemotherapy treatment.With the continuous deepening of research,ADC has achieved good application results in various solid tumor clinical applications,and provided a new treatment plan for gastric cancer patients who have failed conventional chemotherapy.Therefore,in-depth analysis of ADC molecular structure,mechanism of action,indications in clinical application,medication regimen selection,and safety management is of great significance for the rational clinical use of such drugs.This article reviews the molecular structure,mechanism of action,research progress of novel ADCs,and application of ADCs in gastric cancer patients,in order to provide a reference for the rational clinical use of ADC drugs.
作者
朱文兵
郭超
戴钰洁
秦越
周姜平
朱文靖
ZHU Wenbing;GUO Chao;DAI Yujie;QIN Yue;ZHOU Jiangping;ZHU Wenjing(Pharmaceutical Center of Hefei Cancer Hospital,Chinese Academy of Sciences,Hefei 230031,China)
出处
《药学前沿》
2025年第5期877-886,共10页
China Pharmacist
关键词
抗体偶联药物
靶向治疗
胃癌患者
研究进展
应用现状
Antibody-drug conjugates
Targeted therapy
Gastric cancer patients
Research progress
Application Status
